Vgn-R13
Amyotrophic Lateral Sclerosis
Hong ChenEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
150 Active assets in the Amyotrophic Lateral Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAURURSODIOL Amylyx Pharmaceuticals Inc. | Phase 3 | BBB |
Tofersen Biogen | Phase 4 | BBB |
Riluzole AB Science | Phase 4 | BB |
Mexiletine Bjorn Oskarsson, MD | Phase 4 | BB |
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II) Collaborative Medicinal Development Pty Limited | Phase 2/3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →